10-K: Centessa Pharmaceuticals Reports 2024 Financial Results, Highlights Orexin Agonist Program Progress

Centessa Pharmaceuticals' 2024 10-K filing details the company's financial status, pipeline advancements, and strategic shifts, focusing on its orexin agonist program and LockBody technology platform.

Summary

• Centessa Pharmaceuticals, a clinical-stage company, filed its Form 10-K for the fiscal year ended December 31, 2024.
• The company is focused on discovering and developing transformational medicines, particularly in the orexin receptor 2 (OX2R) agonist program.
• Centessa is advancing clinical development of ORX750, with Phase 2 clinical data expected in 2025 for narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH).
• Clinical development of ORX142 is planned, aiming for proof of concept in sleep-deprived healthy volunteers in 2025.
• ORX489, another OX2R agonist, is in IND-enabling activities for neuropsychiatric disorders.
• The company discontinued the SerpinPC program for hemophilia B and LB101 for solid tumors to prioritize the OX2R agonist program.
• Centessa entered a license agreement with Genmab for its LockBody technology platform, receiving an upfront payment of $15 million.
• As of June 30, 2024, the aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant was approximately $621,502,000.
• As of March 10, 2025, the registrant had outstanding 133,184,349 ordinary shares.
• The company had $482.2 million in cash and cash equivalents and short-term investments as of December 31, 2024, expected to fund operations into mid-2027.
• The company anticipates needing substantial additional funds to advance its product candidates.
• The company's loan facility with Oxford Finance contains operating and financial covenants that restrict its business and financing activities.
• As of March 1, 2025, the company had 77 full-time employees, with 49 in research and development and 28 in business development, finance, legal, and administration.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While there's progress in the orexin agonist program and a new licensing deal, the company is still operating at a loss and requires additional funding. The discontinuation of other programs and the risks associated with drug development temper the positive aspects.

Positives

• Advancing clinical development of ORX750 with Phase 2 clinical data expected in 2025.
• Initiating clinical development of ORX142, aiming for proof of concept in sleep-deprived healthy volunteers in 2025.
• Progressing development of ORX489 for neuropsychiatric disorders.
• License agreement with Genmab provides upfront payment and potential future revenue.
• Phase 1 data for ORX750 shows increased wakefulness and a favorable safety profile.
• The company has a track record of making judicious capital and resource allocation decisions for discovery and development efforts across our portfolio, and expeditiously evaluating and terminating programs when the data do not support advancement.

Negatives

• The company has incurred net losses since inception and expects to continue to incur losses.
• The company will need substantial additional funds to advance development of its product candidates.
• The company's loan facility contains operating and financial covenants that restrict its business and financing activities.
• Product candidates are in various stages of development and may fail or suffer delays.
• The company relies on third parties to conduct preclinical studies and clinical trials.
• The company may not be successful in identifying, discovering, in-licensing or otherwise acquire additional product candidates and may fail to capitalize on programs or product candidates that may be a greater commercial opportunity or for which there is a greater likelihood of success.

Risks

• The company may not be successful in its efforts to use its differentiated asset-centric approach to drug discovery and development to build a pipeline of product candidates with commercial value.
• A single or limited number of programs, developmental assets or product candidates may comprise a large proportion of the company's value.
• The company faces challenges, risks and expenses related to its operations as well as the management of the expected growth in the scale and complexity of its operations.
• The company's loan facility and payment obligations under the Loan and Security Agreement with Oxford Finance contain operating and financial covenants that restrict its business and financing activities.
• The company's product candidates are in various stages of development and may fail in development or suffer delays that materially adversely affect their commercial viability.
• The company may be unable to obtain U.S. or foreign regulatory approval and, as a result, unable to develop and/or commercialize its product candidates.
• The company relies on third parties to conduct its preclinical studies and clinical trials and if these third parties perform in an unsatisfactory manner, its business could be substantially harmed.
• Business interruptions resulting from the Russia-Ukraine war, the Middle East conflict(s), tensions in U.S. China relations, or similar geo-political conflicts could cause a disruption to the company's business activities.
• If the company is unable to obtain and maintain sufficient patent and other intellectual property protection for its product candidates and technology, its competitors could develop and commercialize similar products.
• The company is an emerging growth company and a smaller reporting company, and the reduced reporting requirements may make its ADSs less attractive to investors.
• The company previously had material weaknesses in its internal control systems over financial reporting, which have been remediated, but new material weaknesses may be identified in the future.
• If the company fails to develop or maintain an effective system of disclosure controls and internal control over financial reporting, its ability to produce timely and accurate financial statements or comply with applicable regulations could be impaired.
• Holders of ADSs may be subject to limitations on the transfer of their ADSs and the withdrawal of the underlying ordinary shares.
• There is uncertainty as to whether the company is or will be a PFIC, which could have material adverse U.S. federal income tax consequences to U.S. holders.

Future Outlook

Centessa expects to share Phase 2 clinical data for ORX750 in 2025 and initiate clinical development of ORX142, aiming for proof of concept in sleep-deprived healthy volunteers in 2025.

Management Comments

• The company is focused on discovering and developing transformational medicines for patients.
• The company has a track record of making judicious capital and resource allocation decisions for discovery and development efforts across our portfolio, and expeditiously evaluating and terminating programs when the data do not support advancement.

Industry Context

The biotechnology and pharmaceutical industries are characterized by rapid technological evolution, intense competition, and a strong emphasis on intellectual property, with Centessa facing competition from major pharmaceutical, specialty pharmaceutical, and emerging biotechnology companies.

Comparison to Industry Standards

• The orexin agonist market is being pursued by companies like Takeda, Jazz, Harmony, Eisai Co., Ltd., and Alkermes plc.
• Revenue associated with oxybate products (Xyrem and Xywav) indicated for narcolepsy and IH was over $2 billion in 2024, indicating the market potential for sleep disorder treatments.
• The company's approach to drug discovery and development is differentiated and asset-centric, which may be unique compared to more traditional licensing and collaboration approaches.

Legal Proceedings

• The company and certain of its current and former officers were named as defendants in a proposed class-action lawsuit, which was subsequently dismissed with prejudice.

Related Party Transactions

• The company has entered into Master Services agreements with certain drug discovery companies affiliated with David Grainger, former Chief Innovation Officer.

Stakeholder Impact

• Shareholders may experience dilution from future equity offerings.
• Employees may be affected by changes in compensation plans or potential layoffs.
• Patients may benefit from the development of new treatments for sleep and neuropsychiatric disorders.
• Suppliers and creditors may be impacted by the company's financial performance and ability to meet its obligations.

Next Steps

• Advance clinical development of ORX750, aiming to share Phase 2 clinical data in 2025.
• Initiate clinical development of ORX142, aiming for proof of concept in sleep-deprived healthy volunteers in 2025.
• Progress development of ORX489 for neuropsychiatric disorders.
• Continue research efforts on differentiated pharmacology associated with the activation of the orexin system.
• Evaluate the LockBody platform for its potential to deliver potent effectors into the TME while avoiding systemic toxicity.

Key Dates

Keywords

ORX750, Orexin Agonist, LockBody, Clinical Trials, Drug Development, Pharmaceuticals, Centessa